Asra Al Fauzi, Asra and Krisna Tsaniadi Prihastomo, Krisna and I. G. M. Aswin R. Ranuh, Aswin and Tedy Apriawan, Tedy and Joni Wahyuhadi, Joni and M. Arifin Parenrengi, Arifin and Agus Turchan, Agus and Abdul Hafid Bajamal, Abdul and Hari Basuki Notobroto, Hari Clinical Outcomes of MLC601 (NeuroAiDTM) in Traumatic Brain Injury: A Pilot Study. Brain Sciences, 10 (2). ISSN 2076-3425

	Text (Artikel) 12. Artikel__compressed.pdf Download (2MB)
	Text (Turnitin) 12. turnitin.pdf Download (1MB)
	Text (PENILAIAN KARIL) 12. karil.pdf Download (145kB)

Abstract

Abstract Background: MLC601 is a natural product formulation from Chinese medicine that is extensively studied in ischemic stroke. Traumatic brain injury (TBI) shares pathophysiological mechanisms with ischemic stroke, yet there are few studies on the use of MLC601 in treating TBI. This Indonesian pilot study aimed to investigate clinical outcomes of MLC601 for TBI. Methods: This randomized controlled trial included subjects with nonsurgical moderate TBI allocated into two groups: with and without MLC601 over three months in addition to standard TBI treatment. Clinical outcomes were measured by the Glasgow Outcome Scale (GOS) and Barthel Index (BI) observed upon discharge and at months (M) 3 and 6. Results: Thirty-two subjects were included. The MLC601 group (n = 16) had higher GOS than the control group (n = 16) at all observation timepoints, though these differences were not statistically significant (p = 0.151). The BI values indicated a significant improvement for the MLC601 group compared to the control group at M3 (47.5 vs. 35.0; p = 0.014) and at M6 (67.5 vs. 57.5; p = 0.055). No adverse effects were associated with MLC601 treatment. Conclusion: In this cohort of nonsurgical moderate TBI subjects, MLC601 showed potential for a positive effect on clinical outcome with no adverse effects

Actions (login required)

View Item